World’s First Minimally Invasive Soft Robotic Cardiac Device to Treat
With a lead investment from Wellcome Trust, CorInnova is developing a minimally invasive, soft robotic cardiac device in order to create a new paradigm for heart failure treatment. The device is intended to treat the large number of patients who are contra-indicated for the state-of-the-art left ventricular assist devices (LVADs), thereby reaching three to four times as many eligible patients. The device may also reverse the progression of heart failure or even prevent its development in post-heart attack patients.
The device is a collapsible, biventricular soft robotic muscle that can be delivered and secured to the heart in a minimally invasive manner. The device conforms to the heart’s surface, and gently compresses the heart to increase cardiac output using a pneumatic driver that operates in synchrony with the heartbeat.
The device's minimally invasive nature should make it suitable for the large number of patients too frail to withstand the extensive surgery needed for LVADs. More importantly, the device increases cardiac output without touching the blood, thereby overcoming the limitations of all current circulatory assist devices, which touch the blood and so are prone to significant complications resulting from blood contact, such as high rates of stroke and gastrointestinal bleeding.
The device has shown the ability to increase cardiac output by up to 50% in large animal studies in an acute heart failure model. The device also improves diastolic function, potentially treating diastolic heart failure patients who have no current device treatments. Addressable markets are up to $15 billion. CorInnova has created a world class team to develop and commercialize this technology.
News & Press Releases
Awards & Recognition
None of the statements or information contained on our website is an offer to buy or sell our securities. Offers to buy or sell our securities are made only pursuant to separate formal legal agreements. Nor should you make any investment decision based on the information on our website, but solely on that information contained in such legal agreements.